Eftilagimod Alfa Plus Pembrolizumab in NSCLC (TACTI-004)

Find a trial Researchers Sponsors Patients Company

Bridging the gap between
patient and clinic.

Address

1/457-459 Elizabeth St, Surry Hills NSW 2010

Drop us a line

info@clinrol.com

Products & services

Find a clinical trial Patient recruitment

Company

About Contact us Privacy Policy Terms of Service Trust centre

Conditions

Hyperemesis gravidarum

Multiple sclerosis

Type 2 diabetes

Traumatic brain injury (TBI)

Prostate cancer

Alzheimer's disease

Parkinson's disease

Cardiovascular disease

View all conditions

ABN: 29 640 485 105 © 2025 Clinrol. All Rights Reserved.

Eftilagimod Alfa Plus Pembrolizumab in NSCLC (TACTI-004)